Capsugel Colorista technology can provide a shorter development time for your product while offering the flexibility to progress with technical development before the final commercial colour decision is taken.
Capsugel Colorista technology can provide a shorter development time for your product while offering the flexibility to progress with technical development before the final commercial colour decision is taken.
Commercial colour decisions are rarely made before initial stability studies, which can result in costly delays if new colours are introduced. One major concern when developing a new drug is the ability to anticipate upfront interactions between fill and capsule.
Capsugel Colorista capsules are a new single research and development (R&D) solution for pharmaceutical formulation development. It allows the ability to progress with compatibility and stability testing before deciding on a colour for the commercial drug product. Capsugel Colorista capsules are the perfect tool for pharmaceutical customers that are looking for flexible and time-efficient development of new products or generics.
Capsugel Colorista is available in Coni-Snap gelatin and Vcaps Plus capsules, which contains a selection of colourants and printing inks with a broad geographic scope. It is an optimised tool for formulation development and enabling compatibility studies before deciding on the final colour for commercial drug products.
The top reasons for choosing Capsugel Colorista capsules include:
Data generated using Capsugel Colorista capsules can be used for regulatory submission, provided that the colour composition of the final drug product contains only colourants from the Colorista capsule colour formulation in an amount that does not exceed the original amount.
By using stability data from the Capsugel Colorista capsules to support the marketing authorisation application (MAA), time can be gained in obtaining regulatory approval.
Click here for more information.